Refine
Year of publication
Document Type
- Preprint (105)
- Article (89)
- Working Paper (3)
Has Fulltext
- yes (197) (remove)
Is part of the Bibliography
- no (197)
Keywords
- HIV (2)
- LHC (2)
- 900 GeV (1)
- ABC transporters (1)
- ALICE (1)
- ALICE detector (1)
- APRI (1)
- ATPases (1)
- Acute myeloid leukemia (1)
- Amizon (1)
- Anti-nuclei (1)
- B cell receptor (1)
- Berci needle (1)
- Blood flow restriction (1)
- Brent (1)
- C-reactive protein (1)
- CABG (1)
- COVID-19 (1)
- Centrality Class (1)
- Centrality Selection (1)
- Circulating miRNA (1)
- Cognitive-motor interference (1)
- Direct Acting Antivirals (DAA) (1)
- Drug screens (1)
- Dual task walking (1)
- Dumon stents (1)
- Electron-pion identification (1)
- Endurance training (1)
- FAV00A (1)
- FIB-4 (1)
- Fibre/foam sandwich radiator (1)
- Fibrotest (1)
- Gait analysis (1)
- HBV (1)
- HCV (1)
- Haploidentical stem cell transplantation (1)
- Hematology (1)
- Hepatitis C (1)
- Hepatotoxicity (1)
- Inflammation (1)
- Ionisation energy loss (1)
- KIR (1)
- Leukemias (1)
- Liver enzymes (1)
- MLL (1)
- Marisa cornuarietis (1)
- Minimal detectable change (1)
- Minimal residual disease (1)
- Minimum Bias (1)
- Multi-wire proportional drift chamber (1)
- Neural network (1)
- Older adults (1)
- Oncology (1)
- PYTHIA (1)
- Pb–Pb collisions (1)
- Phosphate (1)
- Positive fluid balance (1)
- Postoperative atrial fibrillation (1)
- RNA polymerase (1)
- Resolution Parameter (1)
- Retail gasoline price (1)
- SARS-CoV-2 (1)
- Sustained virological response (SVR) (1)
- TR (1)
- Time Projection Chamber (1)
- Tracking (1)
- Transient elastography (1)
- Transition radiation detector (1)
- Transverse momentum (1)
- Trigger (1)
- Valve surgery (1)
- Verbal fluency (1)
- WTI (1)
- X-ray crystallography (1)
- Xenon-based gas mixture (1)
- acoustic radiation force impulse imaging (1)
- airway (1)
- angiopoietin-like 3 (ANGPTL3) (1)
- arteriogenesis (1)
- axions (1)
- biomarker (1)
- bisphenol A (1)
- blood flow restriction (1)
- cART (1)
- circulating miRNA (1)
- co-infection (1)
- component study (1)
- cone-beam computed tomography (CBCT) (1)
- cone-beam computer tomography (1)
- cryo-EM (1)
- dE/dx (1)
- dark matter experiments (1)
- denervation (1)
- direct-acting antivirals (1)
- electromagnetic navigation bronchoscopy (EMN, ENB) (1)
- endocrine disruptor (1)
- expert forecasts (1)
- fibrotest (1)
- forecast combination (1)
- hazard assessment (1)
- hepatic fibrosis (1)
- hepatitis C (1)
- hepatitis C virus (1)
- insulin resistance (1)
- low-dose effects (1)
- membrane proteins (1)
- miR-142-5p (1)
- miR-143-3p (1)
- miR-197-3p (1)
- miR-342-3p (1)
- miR-424-5p (1)
- mindfulness (1)
- molecular dynamics simulation (1)
- molecular machines (1)
- non-invasive fibrosis assessment (1)
- oil market (1)
- peripheral artery disease (1)
- phylogeny (1)
- point shear wave elastography (1)
- primary active transporters (1)
- prosobranchia (1)
- psychotherapy process (1)
- pulmonary hypertension (1)
- radiation (1)
- randomized controlled trial (RCT) (1)
- real-time data (1)
- reproductive toxicity (1)
- sequence alignment (1)
- shortening of treatment (1)
- solar physics (1)
- solitary pulmonary nodule (1)
- sphingolipid (1)
- stent (1)
- stopping rule (1)
- strength training (1)
- structural biology (1)
- superfemale (1)
- survey expectations (1)
- temperature (1)
- therapeutic alliance (1)
- tracheobronchomalacia (1)
- transbronchial biopsy (TBB) (1)
- transient elastography (1)
- white and brown dwarfs (1)
- xenoestrogen (1)
- гепатит С (1)
- правила прекращения лечения (1)
- противовирусные препараты прямого действия (ПППД) (1)
- сокращение лечения (1)
- устойчивый вирусологический ответ (УВО) (1)
Institute
- Physik (167)
- Frankfurt Institute for Advanced Studies (FIAS) (154)
- Informatik (147)
- Medizin (20)
- Exzellenzcluster Die Herausbildung normativer Ordnungen (2)
- Hochschulrechenzentrum (2)
- Institut für Ökologie, Evolution und Diversität (2)
- Philosophie (2)
- Psychologie und Sportwissenschaften (2)
- Rechtswissenschaft (2)
Members of the ATP‐binding cassette (ABC) transporter superfamily translocate a broad spectrum of chemically diverse substrates. While their eponymous ATP‐binding cassette in the nucleotide‐binding domains (NBDs) is highly conserved, their transmembrane domains (TMDs) forming the translocation pathway exhibit distinct folds and topologies, suggesting that during evolution the ancient motor domains were combined with different transmembrane mechanical systems to orchestrate a variety of cellular processes. In recent years, it has become increasingly evident that the distinct TMD folds are best suited to categorize the multitude of ABC transporters. We therefore propose a new ABC transporter classification that is based on structural homology in the TMDs:
Poster presentation: Background In the past years, once-daily (QD) dosing of antiretroviral combination therapy has become an increasingly available treatment option for HIV-1+ patients. Methods Open label study in which HIV-1+ patients treated with SAQ/RTV (1000/100 mg BID) and two NRTIs with HIV-RNA-PCR < 50 copies/ml were switched to SAQ/RTV(2000/100 mg QD) with unchanged NRTI-backbone. CD4-cells, HIV-RNA-PCR, SAQ and RTV drug-levels and metabolic parameters were compared. Summary of results 17 patients (15 male, 42 years), median CD4 456 ± 139/micro l were included so far. The median follow-up time is 4 months. The HIV-RNA-PCR remained <50 copies/ml for all patients. Fasting metabolic parameters remained unchanged. The SAQ AUC 0–12 h were significantly higher when given QD vs. BID (median 29,400 vs. 18,500 ng*h/ml; p = 0.009), whereas the Cmin, Cmax and AUC was lower for RTV when given QD vs. BID (7,400 vs. 11,700 ng*h/ml; p = 0.02). Conclusion In this ongoing study SAQ/RTV (2000/100 mg QD) was well tolerated and demonstrated higher SAQ and lower RTV drug levels as compared to the BID dosing schedule. (Table 1 and Figure 1.)
Poster presentation: Purpose of the study To compare the lipometabolic profiles of three double-boosted protease inhibitor (PI) regimens at standard dose, containing saquinavir and ritonavir in combination with lopinavir (LOPSAQ), atazanavir (ATSAQ) or fosamprenavir (FOSAQ) in HIV-positive patients, treated without reverse transcriptase inhibitors (RTI). ...
Background and aims: Individualization of treatment with peginterferon alfa and ribavirin in patients with chronic hepatitis C showed benefit in controlled trials and was implemented in treatment guidelines to increase response rates and to reduce side effects and costs. However, it is unknown whether individualization was adopted in routine daily practice and whether it translated into improved outcomes.
Methods: From a large noninterventional cohort study, clinical and virologic response data of 10,262 HCV patients who received peginterferon alfa-2a and ribavirin between 2003-2007 and 2008-2011 were analyzed. To account for treatment individualization, a matched-pair analysis (2,997 matched pairs) was performed. Variation in treatment duration and dosing of ribavirin were analyzed as indicators for individualization.
Results: Sustained virological response (SVR) rates were similar between 2003-2007 and 2008-2011 (62.0% vs. 63.7%). Patients with comorbidities were more abundant in the later period, (44.3% vs. 57.1%). The subsequent matched-pair analysis demonstrated higher SVR rates in the 2008-2011 period (64.3%) than in the 2003-2007 period (61.2%, p=0.008). More patients received abbreviated or extended treatment regimens in the later than the earlier period as an indicator of treatment individualization. To the same end, ribavirin doses were higher in the later period (12.6 versus 11.6 mg/kg/day). Factors independently associated with SVR included HCV genotype, low baseline viral load, younger age, route of infection, absence of concomitant diseases, lower APRI score, normal gamma-GT, higher ribavirin doses, no substitution for drug abuse, treatment duration, and treatment in the 2008-2011 period.
Conclusions: Treatment individualization with peginterferon alfa and ribavirin was implemented in daily routine between 2003-2007 and 2008-2011, SVR rates improved in the same period. These findings may be most relevant in resource-limited settings.
Previous investigations have shown that bisphenol A (BPA) induces a superfeminization syndrome in the freshwater snail Marisa cornuarietis at concentrations as low as 1 μg/L. Superfemales are characterized by the formation of additional female organs, enlarged accessory sex glands, gross malformations of the pallial oviduct, and a stimulation of egg and clutch production, resulting in increased female mortality. However, these studies were challenged on the basis of incomplete experimentation. Therefore, the objective of the current approach was to bridge several gaps in knowledge by conducting additional experiments. In an initial series of experiments, study results from the reproductive phase of the snails were evaluated in the sub-micrograms per liter range. Before and after the spawning season, superfemale responses were observed [NOEC (no observed effect concentration) 7.9 ng/L, EC10 (effective concentration at 10%) 13.9 ng/L], which were absent during the spawning season. A further experiment investigated the temperature dependence of BPA responses by exposing snails at two temperatures in parallel. The adverse effect of BPA was at least partially masked at 27°C (EC10 998 ng/L) when compared with 20°C (EC10 14.8 ng/L). In M. cornuarietis, BPA acts as an estrogen receptor (ER) agonist, because effects were completely antagonized by a co-exposure to tamoxifen and Faslodex. Antiandrogenic effects of BPA, such as a significant decrease in penis length at 20°C, were also observed. Competitive receptor displacement experiments indicate the presence of androgen- and estrogen-specific binding sites. The affinity for BPA of the estrogen binding sites in M. cornuarietis is higher than that of the ER in aquatic vertebrates. The results emphasize that prosobranchs are affected by BPA at lower concentrations than are other wildlife groups, and the findings also highlight the importance of exposure conditions.
We welcome critical appraisals that help to provide balance; however, Dietrich et al. gave an unjustified reproach. We feel that Dietrich’s position is severely compromised because he serves as an expert for the bisphenol A (BPA) Industry Group (Brussels, Belgium). We would like to respond to the issues raised by Dietrich et al., as well as to their oversights and inappropriate interpretations of our findings...
This report describes the clinical courses of two acute myeloid leukemia patients. Both had MLL translocations, the first a t(10;11)(p11.2;q23) with MLL-AF10 and the second a t(11;19)(q23;p13.1) with MLL-ELL fusion. They achieved a clinical remission under conventional chemotherapy but relapsed shortly after end of therapy. Both had a history of invasive mycoses (one had possible pulmonary mycosis, one systemic candidiasis). Because no HLA-identical donor was available, a haploidentical transplantation was performed in both cases. Using a specially designed PCR method for the assessment of minimal residual disease (MRD), based on the quantitative detection of the individual chromosomal breakpoint in the MLL gene, all patients achieved complete and persistent molecular remission after transplantation. The immune reconstitution after transplantation is described in terms of total CD3+/CD4+, CD3+/CD8+, CD19+, and CD16+/CD56+ cell numbers over time. The KIR and HLA genotypes of donors and recipients are reported and the possibility of a KIR-mediated alloreactivity is discussed. This report illustrates that haploidentical transplantation may offer a chance of cure without chronic graft-versus-host disease in situations where no suitable HLA-identical donor is available even in a high-risk setting and shows the value of MRD monitoring in the pre- and posttransplant setting.